Regional Overviews

Europe CIS

Europe CIS provides a broad range of Sterile Focus and Regional Brands while operating a range of manufacturing facilities for Aspen’s own production needs, as well as manufacturing for third parties. Sterile Focus Brands comprise anaesthetics and thrombosis in Russia and the other CIS countries only. Manufacturing activities include active pharmaceutical ingredients (“APIs”) and FDF production and our sites are widely accredited. The prefilled syringe and multi-dose form sites in France and Germany respectively, provide FDF medicines for commercialisation by Aspen and third parties for both domestic and export markets.

Key Countries

France
Germany
Ireland
Netherlands
Russian Federation

Overview

Brand Therapeutic category

Arixtra

Antithrombotic agent

Diprivan

General anaesthetic

Ovestin

Estrogen hormone replacement

Ultiva

Injectable general anaesthetic

Xylocaine

Regional anaesthetic

Products
Launched

(2021: Nil)

0
Product
Recalls

(2021: 2)

0 %
Average Staff
Turnover

(2021: 11%)

Work-related
Facilities

(2021: Nil)

50
Sales
Representatives

(2021: 149)

900
Permanent
Employees

(June 2021: 2,194)

Revenue 2022
R’million
2021 (CER)
R’million
Change
%

Commercial Pharmaceuticals

4 737

4 931

(4)

Regional Brands

1 594

1 582

1

Sterile Focus Brands

3 143

3 349

(6)

Manufacturing

8 368

7 783

8

FDF

3 175

2 104

51

API Biochem

778

1 161

(33)

API Chemicals

4 415

4 518

(2)

Total

13 105

12 714

3

Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture.

Contribution to Group revenue (%)
2022
Revenue by segment (%)
2022

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.